Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Atkinson

Showing results (841-850 of 1,094) with videos related to

Pageof 110
Sort By:
British Dental Journal|February 14, 2006
Commercialism in marketingM Atkinson, R Bevan, S Becker, et al.
JCO Oncology Practice|February 20, 2020
Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer CentersAngela M Stover, Benjamin Y Urick, Allison M Deal, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older womenNeil Carleton, Sanghoon Lee, Ruxuan Li, et al.
JAMA Oncology|August 14, 2015
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Amylou C Dueck, Tito R Mendoza, Sandra A Mitchell, et al.
Circulation. Cardiovascular Imaging|July 13, 2012
In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humansJennifer M J Richards, Catherine A Shaw, Ninian N Lang, et al.
JCO Oncology Practice|March 6, 2025
Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01)Thomas M Atkinson, Madhu Mazumdar, Grace Van Hyfte, et al.
Nature Cancer|June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacyDong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 5, 2023
Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03Thomas M Atkinson, Shelly Lensing, Jeannette Y Lee, et al.
The New England Journal of Medicine|June 15, 2022
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal CancerJoel M Palefsky, Jeannette Y Lee, Naomi Jay, et al.
Radiation Protection Dosimetry|August 28, 2012
Realising the European Network of Biodosimetry (RENEB)U Kulka, L Ainsbury, M Atkinson, et al.
Pageof 110

Showing results (841-850 of 1,094) with videos related to

Sort By:
Pageof 110
British Dental Journal|February 14, 2006
Commercialism in marketingM Atkinson, R Bevan, S Becker, et al.
JCO Oncology Practice|February 20, 2020
Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer CentersAngela M Stover, Benjamin Y Urick, Allison M Deal, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
Systemic and local chronic inflammation and hormone disposition promote a tumor-permissive environment for breast cancer in older womenNeil Carleton, Sanghoon Lee, Ruxuan Li, et al.
JAMA Oncology|August 14, 2015
Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)Amylou C Dueck, Tito R Mendoza, Sandra A Mitchell, et al.
Circulation. Cardiovascular Imaging|July 13, 2012
In vivo mononuclear cell tracking using superparamagnetic particles of iron oxide: feasibility and safety in humansJennifer M J Richards, Catherine A Shaw, Ninian N Lang, et al.
JCO Oncology Practice|March 6, 2025
Health-Related Quality of Life for Persons Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (AMC-A01)Thomas M Atkinson, Madhu Mazumdar, Grace Van Hyfte, et al.
Nature Cancer|June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacyDong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 5, 2023
Construct validity and responsiveness of a health-related symptom index for persons either treated or monitored for anal high-grade squamous intraepithelial lesions (HSIL): AMC-A01/-A03Thomas M Atkinson, Shelly Lensing, Jeannette Y Lee, et al.
The New England Journal of Medicine|June 15, 2022
Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal CancerJoel M Palefsky, Jeannette Y Lee, Naomi Jay, et al.
Radiation Protection Dosimetry|August 28, 2012
Realising the European Network of Biodosimetry (RENEB)U Kulka, L Ainsbury, M Atkinson, et al.
Pageof 110